Clinical Trial Update: A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind study evaluated three dose levels of MSDC-0602 for safety, tolerability, and efficacy in adults with Type 2 diabetes mellitus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MSDC-0602 (MSDC-0602)

Snippet

Sponsor: Metabolic Solutions Development Company | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2013-12-20